絞り込み

16646

広告

東北電力 女川原発2号機 地元自治体が再稼働をどう判断か注目 (NHK)

26日、原子力規制委員会の審査に合格した宮城県にある女川原子力発電所2号機について国と東北電力は、再稼働に必要な自治体の同意に向けた手続きを進めることになり今後...

  1. 無観客ライブを無料配信 会場費などはファ...
  2. 突然の異常行動を伴う頭痛、疑うべき疾患は...
  3. COVID-19の拡大で重み増す保健所長...
  4. SARS-CoV-2が眼から感染する可能...

ニュース一覧

The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach.

著者 Levin J , Maaß S , Schuberth M , Respondek G , Paul F , Mansmann U , Oertel WH , Lorenzl S , Krismer F , Seppi K , Poewe W , Wenning G , , Giese A , Bötzel K , Höglinger G
J Neural Transm (Vienna).2016 Jan 25 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (4view , 1users)

Full Text Sources

Medical

Formation of toxic α-synuclein oligomers appears to be a key underlying pathological mechanism of synucleinopathies such as Parkinson's disease or multiple system atrophy (MSA). Given that Epigallocatechin-gallate has been shown to inhibit α-synuclein aggregation, it might represent a causal treatment option. Therefore, we set out to evaluate the safety, tolerability and a potential disease-modifying effect of Epigallocatechin-gallate in patients with MSA after 48 weeks of treatment. Power calculation was performed on existing natural history data on the progression of the Unified MSA Rating Scale as primary readout parameter. To assess the efficacy of Epigallocatechin-gallate versus placebo regarding the reduction of disease progression measured during the study period (80 % power, 5 % p level, 50 % effect size) 36 patients per group are needed. Considering a drop-out rate of 20 % a total of 86 patients will be recruited in this multicentre study. These data provide a solid rationale to investigate whether supplementation of Epigallocatechin-gallate can delay the progression of the MSA-related disability.
PMID: 26809243 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード